Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.
J Exp Med
; 218(12)2021 12 06.
Article
en En
| MEDLINE
| ID: mdl-34623376
ABSTRACT
Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD-specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Polisacáridos
/
Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo
/
Glicoproteína de la Espiga del Coronavirus
/
Anticuerpos ampliamente neutralizantes
/
SARS-CoV-2
/
COVID-19
/
Anticuerpos Antivirales
Límite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Exp Med
Año:
2021
Tipo del documento:
Article
País de afiliación:
Japón